研究项目库 / NCT04728893

Nemtabrutinib用于血液系统恶性肿瘤的II 期研究

这是一项关于血液系统恶性肿瘤的II 期研究,登记的药物或干预包括Nemtabrutinib,当前状态为招募中。登记地点显示中国合肥、北京、重庆、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。

一分钟看懂

这是一项关于血液系统恶性肿瘤的II 期研究,登记的药物或干预包括Nemtabrutinib,当前状态为招募中。登记地点显示中国合肥、北京、重庆、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。

药物或干预

Nemtabrutinib · II 期

登记条件中文摘要

年龄范围:18岁及以上

登记的基本范围为不限性别,年龄18岁及以上;以下仅摘录8项专业入选条件,需结合英文原文并由研究团队确认。

登记记录列出8项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。

中国哪些地方有记录

以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。

  • Anhui Provincial Hospital ( Site 2808) · 合肥
  • Peking University Third Hospital-Hematology ( Site 2827) · 北京
  • The Second Affiliated Hospital of Chongqing Medical University ( Site 2825) · 重庆
  • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824) · 广州
  • Liuzhou People's Hospital ( Site 2817) · 柳州
  • Guangxi Medical University Cancer Hospital ( Site 2814) · 南宁
  • Henan Cancer Hospital-hematology department ( Site 2802) · 郑州
  • Wuhan Union Hospital ( Site 2816) · 武汉
  • The Second Xiangya Hospital of Central South University ( Site 2820) · 长沙
  • Hunan Cancer Hospital ( Site 2822) · 长沙
  • Jiangsu Province Hospital ( Site 2823) · 南京
  • The Affiliated Hospital of Xuzhou Medical College ( Site 2818) · 徐州
  • The First Affiliated Hospital of Nanchang University ( Site 2815) · 南昌
  • The First Hospital of Jilin University-Hematology ( Site 2803) · 长春
  • Fudan University Shanghai Cancer Center ( Site 2801) · 上海
  • Huashan Hospital, Fudan University ( Site 2821) · 上海
  • West China Hospital Sichuan University ( Site 2810) · 成都
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800) · 天津
  • The First Affiliated Hospital, Zhejiang University ( Site 2826) · 杭州

入选条件原文摘录

以下为摘录,请打开原始登记查看完整入排标准。

  • * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
  • * Has a life expectancy of at least 3 months, based on the investigator assessment
  • * Has the ability to swallow and retain oral medication
  • * Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
  • * Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • * Has adequate organ function
  • * Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
  • * Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention

联系前需要确认

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

查看登记信息

登记号:NCT04728893;登记信息更新于 2026-11-17;本站同步于 2026-11-21。

查看原始登记记录